Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 189,352,928
  • Shares Outstanding, K 1,767,176
  • Annual Sales, $ 45,804 M
  • Annual Income, $ 4,616 M
  • 60-Month Beta 0.82
  • Price/Sales 4.11
  • Price/Cash Flow 8.13
  • Price/Book 15.66
Trade ABBV with:

Options Overview Details

View History
  • Implied Volatility 24.19%
  • Historical Volatility 29.37%
  • IV Percentile 51%
  • IV Rank 17.33%
  • IV High 138.15% on 12/10/20
  • IV Low 0.29% on 12/16/20
  • Put/Call Vol Ratio 0.35
  • Today's Volume 17,391
  • Volume Avg (30-Day) 43,169
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 368,627
  • Open Int (30-Day) 400,276

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 3.08
  • Number of Estimates 7
  • High Estimate 3.27
  • Low Estimate 2.25
  • Prior Year 2.83
  • Growth Rate Est. (year over year) +8.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
105.56 +1.16%
on 09/20/21
121.53 -12.13%
on 09/01/21
-12.03 (-10.13%)
since 08/20/21
3-Month
105.56 +1.16%
on 09/20/21
121.53 -12.13%
on 09/01/21
-7.91 (-6.90%)
since 06/22/21
52-Week
79.11 +34.98%
on 10/29/20
121.53 -12.13%
on 09/01/21
+18.19 (+20.52%)
since 09/22/20

Most Recent Stories

More News
Tay-Sachs Disease Drugs Market- Worldwide Opportunities, Driving Forces, COVID-19 Impact Analysis, Future Potential 2030

Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region....

SIOX : 2.32 (+7.41%)
PFE : 43.97 (+0.11%)
BAYN : 0.0100 (unch)
BHC : 28.50 (+1.03%)
ABBV : 106.07 (-1.01%)
AMGN : 213.95 (-0.65%)
NOVN : 8.40 (-0.36%)
PROG : 0.9080 (-1.30%)
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA

AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.

REGN : 645.30 (-0.26%)
VRTX : 184.35 (-0.78%)
RGEN : 313.02 (-0.37%)
ABBV : 106.07 (-1.01%)
Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval

Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.

REGN : 645.30 (-0.26%)
BIIB : 287.27 (-2.80%)
RHHBY : 46.1100 (+0.30%)
ABBV : 106.07 (-1.01%)
Global Sterile Injectable Drugs Market Growth to be Propelled by Increasing R&D Initiatives to Witness Considerable GAGR throughout 2021-2029

Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution...

SAN : 3.51 (+3.54%)
PFE : 43.97 (+0.11%)
GSK : 39.31 (+0.59%)
BHC : 28.50 (+1.03%)
ABBV : 106.07 (-1.01%)
AMGN : 213.95 (-0.65%)
NOVN : 8.40 (-0.36%)
PROG : 0.9080 (-1.30%)
JNJ : 163.83 (-0.43%)
Best Dividend Stocks In 2021? 4 To Watch This Week

AAPL : 145.28 (+1.29%)
MMM : 179.81 (+0.78%)
ABBV : 106.07 (-1.01%)
MSFT : 297.78 (+1.01%)
ADM : 59.19 (-1.38%)
AbbVie (ABBV) Stock Moves -1.23%: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $106.40, moving -1.23% from the previous trading session.

ABBV : 106.07 (-1.01%)
AbbVie Submits Regulatory Application to FDA for Risankizumab-rzaa (SKYRIZI®) for the Treatment of Patients 16 Years and Older with Moderate to Severe Crohn's Disease

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction...

ABBV : 106.07 (-1.01%)
Tay-Sachs Disease Drugs Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2030

Research Nester released a report titled "" which delivers detailed overview of the global Tay-Sachs disease drugs market in terms of market segmentation by stage, treatment type, end-user, and by region....

SIOX : 2.32 (+7.41%)
PFE : 43.97 (+0.11%)
BAYN : 0.0100 (unch)
BHC : 28.50 (+1.03%)
ABBV : 106.07 (-1.01%)
AMGN : 213.95 (-0.65%)
NOVN : 8.40 (-0.36%)
PROG : 0.9080 (-1.30%)
Global Sterile Injectable Drugs Market to Witness Considerable growth throughout 2021-2029

Research Nester released a report titled "" which delivers detailed overview of the global sterile injectable drugs market in terms of market segmentation by type, drug class, application, distribution...

SAN : 3.51 (+3.54%)
PFE : 43.97 (+0.11%)
GSK : 39.31 (+0.59%)
BHC : 28.50 (+1.03%)
ABBV : 106.07 (-1.01%)
AMGN : 213.95 (-0.65%)
NOVN : 8.40 (-0.36%)
PROG : 0.9080 (-1.30%)
JNJ : 163.83 (-0.43%)
DiGeorge Syndrome Drug Market Propelled by Increased Patient Pool and R&D Initiatives to Witness Substantial GAGR throughout 2021-2029

Research Nester released a report titled "" which delivers detailed overview of the DiGeorge syndrome drug market in terms of market segmentation by therapy type, route of administration, end-user, and...

PFE : 43.97 (+0.11%)
CERC : 2.93 (-1.68%)
BHC : 28.50 (+1.03%)
NTRA : 125.18 (+1.20%)
ABBV : 106.07 (-1.01%)
AMGN : 213.95 (-0.65%)
NOVN : 8.40 (-0.36%)
PROG : 0.9080 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

3rd Resistance Point 108.85
2nd Resistance Point 108.13
1st Resistance Point 107.64
Last Price 106.07
1st Support Level 106.43
2nd Support Level 105.71
3rd Support Level 105.22

See More

52-Week High 121.53
Last Price 106.07
Fibonacci 61.8% 105.33
Fibonacci 50% 100.32
Fibonacci 38.2% 95.31
52-Week Low 79.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar